The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women's primary physician, where earlier intervention can improve access and outcomes.

Infertility impacts an estimated 10 million women in the United States, yet fewer than 1% receive care at specialized fertility centers, highlighting a significant gap in treatment access. This disparity is further underscored by recent CDC data showing U.S. fertility rates declined to record lows in 2025, continuing a long-term downward trend. By enabling fertility care within the OBGYN setting, where most women already receive care, Femasys is addressing this unmet need with earlier access to intervention at a meaningfully lower cost and reduced procedural complexity than IVF. This approach enables OBGYNs to offer a new in-office fertility treatment option, supporting practice growth while shifting the care pathway toward more timely, cost-efficient, and patient-centered treatment.

"Femasys is leading a fundamental shift in fertility care by moving treatment earlier and closer to the patient," said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. "Following FemaSeed's earlier than expected U.S. FDA clearance and subsequent clinical validation in infertility centers, the availability of FemSperm now expands our capabilities to include in-office sperm preparation, enabling a complete solution in the OBGYN setting. After an exciting ACOG launch, we are focused on rapidly advancing this new model of care."

"When I learned of this new end-to-end fertility solution, I immediately recognized the impact it could have for my patients requiring intervention to achieve pregnancy," said Dr. Finazzo, D.O., of Downriver OBGYN in Trenton, MI. "I am proud to be at the forefront of shifting fertility care into the OBGYN setting with an approach that is easily integrated into clinical practice, well tolerated by patients, and operationally straightforward for staff, including in-office sperm preparation for use with FemaSeed."